Literature DB >> 198661

Selective deficiency of 1,25-dihydroxycholecalciferol. A cause of isolated skeletal resistance to parathyroid hormone.

S A Metz, D J Baylink, M R Hughes, M R Haussler, R P Robertson.   

Abstract

To investigate the role of vitamin D metabolites in the pathogenesis of pseudohypoparathyroidism, we studied an elderly man with a unique variant of the disease, which was characterized by hypocalcemia, elevated serum parathyroid hormone (513 +/- 13 pg per milliliter, mean +/- S.E.M., normal, less than 450) but normal renal responses (phosphate and cyclic AMP) to exogenous parathyroid extract. Treatment with parathyroid extract did not produce a calcemic effect, suggesting an isolated skeletal hyporesponsiveness to parathyroid hormone. Although 25-hydroxyvitamin D levels were not reduced, levels of 1,25-dihydroxycholecalciferol were extremely low (0.52 ng per deciliter; normal 3.3 +/- 0.06, S.D.). Treatment with 1,25-dihydroxycholecalciferol (1 microgram by mouth per day for four days) increased circulating levels to normal (4.60 ng per deciliter) and restored to normal the calcemic response to parathyroid (change in calcium 3.0 mg per deciliter). These data suggest that 1,25-dihydroxycholecalciferol deficiency may explain the skeletal resistance, but not the renal resistance, often present in classic pseudohypoparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 198661     DOI: 10.1056/NEJM197711172972003

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  7 in total

1.  A 6-hour human parathyroid hormone (1-34) infusion protocol: studies in normal and hypoparathyroid subjects.

Authors:  A McElduff; D Lissner; M Wilkinson; C Cornish; S Posen
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

2.  The pathophysiology of bone and joint disease.

Authors:  S L Teitelbaum; P G Bullough
Journal:  Am J Pathol       Date:  1979-07       Impact factor: 4.307

3.  Pseudohypoparathyroidism and hypocalcemic "myopathy". A case report.

Authors:  H Piechowiak; W Gröbner; H Kremer; D Pongratz; J Schaub
Journal:  Klin Wochenschr       Date:  1981-11-02

4.  Resistance to the phosphaturic and calcemic actions of parathyroid hormone during phosphate depletion. Prevention by 1,25-dihydroxyvitamin D3.

Authors:  H J Gloor; J P Bonjour; J Caverzasio; H Fleisch
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

5.  Antiidiotypic PTH antibodies as a cause of elevated immunoreactive parathyroid hormone in idiopathic hypoparathyroidism, a second case: another manifestation of autoimmune endocrine disease?

Authors:  A McElduff; M Lackmann; M Wilkinson
Journal:  Calcif Tissue Int       Date:  1992-08       Impact factor: 4.333

6.  [Hyperparathyroidism in hemodialysis patients: studies on parathyroid regulation and classification problems (author's transl)].

Authors:  R Augustin; W H Hackeng
Journal:  Klin Wochenschr       Date:  1981-11-16

7.  Demonstration of a lack of change in serum 1 alpha,25-dihydroxyvitamin D in response to parathyroid extract in pseudohypoparathyroidism.

Authors:  P W Lambert; B W Hollis; N H Bell; S Epstein
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.